Business
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"TORONTO, Dec. 16, 2025 /CNW/ - Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.","length":318,"tagName":"p"},{"type":"image","alt":"Specific Biologics Inc. (CNW Group/Specific Biologics Inc.)","displaySize":"","headline":null,"caption":"Specific Biologics Inc. (CNW Group/Specific Biologics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/cnwgroup.com/5cca362d5dadfaf2682d65380dd06db9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YOuyl7wMCdH3W2_xX9TT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/5cca362d5dadfaf2682d65380dd06db9","width":400,"height":133}},"href":"https://mma.prnewswire.com/media/2845677/Specific_Biologics_Inc__Specific_Biologics_Welcomes_Accomplished.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Glickman is an accomplished biotechnology executive and serial entrepreneur, with a career spanning more than 30 years across drug development, corporate strategy and commercialization. He has founded or co-founded many notable biopharmaceutical organizations, including StressGen Biotechnologies, Aspreva Pharmaceuticals, and Aurinia Pharmaceuticals. He has led multiple companies from early scientific concept through clinical development, partnerships, commercialization and successful exits, including the US$915 million acquisition of Aspreva Pharmaceuticals.","length":568,"tagName":"p"},{"type":"text","content":"Dr. Glickman has also served on the boards of numerous public and private biotechnology companies, including leadership roles as Chair of Aurinia Pharmaceuticals, ESSA Pharma, enGene, and has held board positions at Eupraxia Pharmaceuticals and Cardiome / Correvio Pharma, amongst others, where he helped scale emerging biotechnology companies into globally competitive organizations. His longstanding work in patient advocacy and community health has also been recognized by groups such as the Lupus Foundation of America, and with numerous leadership honors including the Ernst and Young Entrepreneur of the Year, the Milt Won...